Bladder Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
Select
09-152-B CALGB 90601: A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab (IND #7921, NSC #704865) to gemcitabine, cislpatin, and placebo in patients with Advanced transitional cell carcinoma
Select
09-288-B Identification of genetic determinants of response to neoadjuvant cisplatin-based chemotherapy in urothelial cancer
Select
11-0106 A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Select
11-0646 S1011: A Phase III Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
Select
12-1089 RTOG 0926: A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
12278A Clinical Urology Research Screening Protocol
Select
14578A A Phase I/II Study of E7389 Halichondrin B analog (NSC# 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
15550B Bladder Cancer Sample Collection

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.